SCHEMBL6347181

SCHEMBL6347181

CC(C)S(=O)(=O)NCCOc1ccc(C2(F)CCCC2NS(=O)(=O)C(C)C)cc1

nearest known ligand 0.36

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.36
HTT P42858 2/20 0.36
ALDH1A1 P00352 4/20 0.35
KDM4E B2RXH2 2/20 0.35
CYP1A2 P05177 1/20 0.34
CYP2D6 P10635 1/20 0.34
CYP2C19 P33261 1/20 0.34
HRH3 Q9Y5N1 1/20 0.33
CYP3A4 P08684 1/20 0.33
SLC6A9 P48067 1/20 0.33
SLC6A2 P23975 1/20 0.33
SLC6A4 P31645 1/20 0.33
SLC6A3 Q01959 1/20 0.33
MEN1 O00255 2/20 0.33
KMT2A Q03164 2/20 0.33
TSHR P16473 1/20 0.33
KCNH2 Q12809 1/20 0.33
GAA P10253 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6344547 0.97 ALDH1A1 (0.37) LMNAHTTALDH1A1KDM4ECYP1A2
SCHEMBL6354373 0.94 ALDH1A1 (0.43) LMNAHTTALDH1A1KDM4ECYP1A2
SCHEMBL6342761 0.91 ALDH1A1 (0.42) LMNAHTTALDH1A1KDM4ECYP1A2
SCHEMBL6346460 0.88 MTNR1A (0.43) ALDH1A1HRH3SLC6A2SLC6A4SLC6A3
SCHEMBL6348951 0.85 HRH3 (0.35) LMNAHTTALDH1A1KDM4ECYP1A2
SCHEMBL6350038 0.85 MTNR1A (0.42) ALDH1A1KDM4EHRH3SLC6A2SLC6A4
SCHEMBL6348910 0.83 GRIA4 (0.36) LMNAALDH1A1CYP2D6CYP3A4KCNH2
SCHEMBL6349722 0.82 KDM4E (0.37) LMNAHTTALDH1A1KDM4ECYP1A2
SCHEMBL6347185 0.81 SLC6A9 (0.45) LMNAHTTALDH1A1CYP1A2CYP2D6
SCHEMBL6342952 0.81 GRIA4 (0.40) LMNAHTTMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6900353-B2 Cyclopentyl sulfonamide derivatives ELI LILLY AND COMPANY (US) 2005-05-31 US claimed
US-20040067984-A1 Cyclopentyl sulfonamide derivatives CANTRELL BUDDY EUGENE (US) 2004-04-08 US claimed
EP-1334087-A1 CYCLOALKYLFLUOROSULFONAMIDE DERIVATIVES ELI LILLY AND COMPANY (US) 2003-08-13 EP claimed
WO-2002032858-A1 CYCLOALKYLFLUOROSULFONAMIDE DERIVATIVES ELI LILLY AND COMPANY (US) 2002-04-25 WO claimed
US-6900353-B2 Cyclopentyl sulfonamide derivatives ELI LILLY AND COMPANY (US) 2005-05-31 US disclosed
US-20040067984-A1 Cyclopentyl sulfonamide derivatives CANTRELL BUDDY EUGENE (US) 2004-04-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040067984-A1 Cyclopentyl sulfonamide derivatives GRIN2A, GRIN1, GRIK5 LMNA 4826/4885HTT 909/4885ALDH1A1 642/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.